Results 191 to 200 of about 2,692,536 (314)

Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function

open access: yesEuropean Journal of Heart Failure, EarlyView.
Improving clinical translation of mitoprotective therapies. 31P MRI, phosphorus‐31 magnetic resonance imaging; hiPSC‐CM, human‐induced pluripotent stem cell‐derived cardiomyocyte; IHD, ischaemic heart disease. Abstract Acute myocardial infarction (MI) remains a major cause of death and disability worldwide.
Melanie Paillard   +29 more
wiley   +1 more source

Veterinary nanomedicine: Pros and cons

open access: yesVeterinary Medicine and Science, Volume 9, Issue 1, Page 494-506, January 2023., 2023
Abstract In recent years, nanotechnology has improved life with continuous growth in different fields. Nanoparticles can be employed in industry, imaging, engineering, and various biomedical filed because of their special physicochemical properties like rapid, effective, highly specific solutions, higher stability, biodegradability, biocompatibility ...
Fariba Jafary   +2 more
wiley   +1 more source

A New Enzyme in the Conversion of Propionyl Coenzyme A to Succinyl Coenzyme A [PDF]

open access: yesJournal of Biological Chemistry, 1961
Yoshito Kaziro   +3 more
openaire   +2 more sources

Compound heterozygosity of a De novo 16q24.1 deletion and missense mutation in COX4I1 leads to developmental regression, intellectual disability, and seizures

open access: yesEpilepsia Open, EarlyView.
Abstract The COX4I1 is responsible for encoding a crucial component of cytochrome c oxidase, integral to electron transport in the mitochondrial respiratory chain. Mutations in COX4I1 can result in a rare autosomal recessive disorder characterized by growth retardation, slow weight gain, microcephaly, and potentially, hematologic symptoms such as ...
Zhen Liu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy